Psybio Therapeutics

Receive alerts
Unlisted (US)
Market Cap:
52 weeks high
52 weeks low

In brief

PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues. 

'' Psychoactive medications treat the illness by rewiring the brain through contemplation and a change of perception in combination with psychotherapy vs. Standard of care (SSRI’s, SNRI’s, MAOI’s, NDRI’s, etc…) which  just chemically treat symptoms.''

Working in partnership with Miami University utilizing a proprietary platform technology to biologically synthesize psilocybin and other targeted next generation active compounds in Psilocybe Cubensis and other fungi and plants.